Andrew Booth - 07 Jun 2021 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role: Chief Financial Officer
Signature: /s/ Tryn Stimart, attorney-in-fact
Issuer symbol: ABCL
Transactions as of: 07 Jun 2021
Net transactions value: +$306,000
Form type: 4
Filing time: 09 Jun 2021, 20:30:27 UTC
Next filing: 10 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership
transaction	ABCL	Common Shares	Options Exercise	$114,000	+600,000		$0.1900^*	600,000	07 Jun 2021	Direct
transaction	ABCL	Common Shares	Options Exercise	$192,000	+600,000	+100%	$0.3200^*	1,200,000	07 Jun 2021	Direct
holding	ABCL	Common Shares						116,959	07 Jun 2021	By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABCL	Share Option (right to buy)	Options Exercise	$0	-600,000	-67%	$0.000000	300,000	07 Jun 2021	Common Shares	600,000	$0.1900	Direct	F1
transaction	ABCL	Share Option (right to buy)	Options Exercise	$0	-600,000	-11%	$0.000000	4,950,000	07 Jun 2021	Common Shares	600,000	$0.3200	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to such option vest and become exercisable annually in equal installments over a six-year period, with the first tranche vested on June 15, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.
F2	2,000,000 shares subject to the option vested and became exercisable on March 23, 2020. The remaining 3,550,000 shares (the "Remaining Shares") subject to the option vest and become exercisable as follows: 25% of the Remaining Shares subject to such option vested and became exercisable on August 22, 2020 and the remainder of the Remaining Shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Content

The shares subject to such option vest and become exercisable annually in equal installments over a six-year period, with the first tranche vested on June 15, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.

2,000,000 shares subject to the option vested and became exercisable on March 23, 2020. The remaining 3,550,000 shares (the "Remaining Shares") subject to the option vest and become exercisable as follows: 25% of the Remaining Shares subject to such option vested and became exercisable on August 22, 2020 and the remainder of the Remaining Shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.